Abstract: AIM: To investigate efficacy of GFA-NAC·Mg on rat liver fibrosis. METHODS: Preparation of liver fibrosis model in rats with 25% carbontetrachloride (CCl₄) by subcutaneous injection,GFA-NAC·Mg intraperitoneal injected treating liver fibrosis with 25,50 and 100 mg/kg. All the rats were killed after 8 weeks of administration with grid staining and the levels of Hyp in serum were detected with ELISA assay,the contents of the MDA,SOD,TGF-β₁,PDGF for liver fibrosis and liver tissue were tested. RESULTS: The liver tissue of fibrosis showed stage Ⅲ-Ⅳ.Compared with the model group,the serum of Hyp significantly was reduced after GFA-NAC·Mg treatment.The antioxidant index SOD significantly was increased in liver tissue while MDA was decreased.Liver fibrosis markers TGF-β₁ and PDGF content were decreased. Liver fibrosis was improved after GFA-NAC·Mg treatment in each groups by grid staining. CONCLUSION: GFA-NAC·Mg has a better therapeutic effect on rat liver fibrosis by inhibiting the expression of PDGF and TGF-β₁.

Key words: acetylcysteine magnesium-glycyrrhizin fine antipode dimmers, liver fibrosis, platelet derived growth factor(PDGF), transforming growth factor beta1(TGF-β₁)